Opthea Limited (ASX:OPT)
0.6000
0.00 (0.00%)
Mar 14, 2025, 4:10 PM AEST
Opthea Revenue
Opthea had revenue of 1,000.00 AUD in the half year ending December 31, 2025, a decrease of -99.66%. This brings the company's revenue in the last twelve months to -20.12K. In the fiscal year ending June 30, 2025, Opthea had annual revenue of 222.69K, down -43.29%.
Revenue (ttm)
-20.12K
Revenue Growth
-43.29%
P/S Ratio
-952.02
Revenue / Employee
-609.61
Employees
33
Market Cap
19.15M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 222.69K | -169.99K | -43.29% |
| Jun 30, 2024 | 392.69K | -186.19K | -32.16% |
| Jun 30, 2023 | 578.88K | 290.04K | 100.42% |
| Jun 30, 2022 | 288.84K | 161.37K | 126.61% |
| Jun 30, 2021 | 127.46K | -18.38K | -12.60% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EZZ Life Science Holdings | 61.40M |
| Immuron | 7.48M |
| Neurotech International | 7.07M |
| Noxopharm | 3.40M |
| Proteomics International Laboratories | 3.21M |
| Argenica Therapeutics | 1.01M |
| AdAlta | 608.07K |
| NeuroScientific Biopharmaceuticals | 317.91K |
Opthea News
- 2 days ago - Opthea Transcript: Investor update - Transcripts
- 2 days ago - Opthea Slides: Investor update - Filings
- 6 weeks ago - Opthea Earnings release: Q3 2026 - Filings
- 3 months ago - Opthea Quarterly report: H1 2026 - Filings
- 7 months ago - Opthea Transcript: AGM 2025 - Transcripts
- 8 months ago - Opthea Earnings release: Q1 2026 - Filings
- 10 months ago - Opthea Annual report: H2 2025 - Filings
- 10 months ago - Opthea Annual report: H2 2025 - Filings